Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Once-Daily Administration of Pentasa in Remission Phase Approved; Kyorin Pharmaceutical
August 27, 2012
- Deal with Mylan to Boost Pfizer’s Generic Lineup in Japan with Definite Impact on Competitors
August 27, 2012
- Kyowa Kirin, Otsuka Still Working Out Specifics for Cooperation in Field of Oncology
August 27, 2012
- Forest HD Considering Joint Venture in Indonesia
August 24, 2012
- Pfizer, Mylan Ink Strategic Collaboration in Japan Generics Biz; Aim for No. 3 in Market
August 24, 2012
- Azilva Ranked No. 1 for Third Consecutive Month in Both GP, HP Markets in July: Rep Track Survey
August 23, 2012
- Janssen Pharmaceutical Appoints Goodwin as Next President
August 23, 2012
- Inavir Significantly Prevents Influenza Infection in PIII: Daiichi Sankyo
August 23, 2012
- Eli Lilly Japan Not to File for Listing of Bydureon Due to Expected Rights Return
August 22, 2012
- Shionogi to Launch Quick Flu Diagnostic Kit on September 11
August 22, 2012
- Neoral, Sandimmune Approved for Small Intestine Transplantation: Novartis
August 22, 2012
- Eisai’s Halaven Receives Orphan Drug Designation for Soft-Tissue Sarcoma in US
August 22, 2012
- Pazopanib Approved for aSTS in Europe: GSK
August 22, 2012
- Oncology Japan 2012 to Be Held on November 7, 8
August 22, 2012
- Mediscience Stepping Up Athlete Recruitments as CMRs
August 21, 2012
- ARB Prescription Rate Affected by Doctors’ Evaluations of MRs: M3 Survey
August 21, 2012
- Generic Actos Launched in US; Takeda Grants AG to Teva, Ranbaxy
August 21, 2012
- Astellas to Build New Building to Boost Production Capacity of Investigational Anticancer Drug Substances
August 21, 2012
- DSP to Set Up Cancer Institute Led by CEO of Its US Subsidiary BBI
August 21, 2012
- Synagis IM Liquid Injection Solution Approved: Abbott Japan
August 20, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…